Premenstrual Syndrome Treatment Market Set to Surpass US$ 2,155 Million By 2033 | Astute Analytica
The market is undergoing a significant transformation, moving toward a digitally integrated, personalized care model. Consumer empowerment through accessible OTC products and trusted pharmacy guidance is fueling innovation beyond traditional pain relief into holistic wellness solutions.
Chicago, Oct. 27, 2025 (GLOBE NEWSWIRE) — The global premenstrual syndrome treatment market was valued at US$ 1,501 million in 2024 and is projected to reach US$ 2,155 million by 2033, growing at a CAGR of 4.1% during the 2025 to 2033 period.
The foundation of premenstrual syndrome treatment market growth is being built in today’s research labs. The pipeline for new therapies is expanding at a remarkable rate. In 2024, an impressive 12 new Phase II clinical trials were initiated specifically for premenstrual dysphoric disorder drugs. Furthermore, a significant 25 novel drug candidates entered preclinical development for premenstrual syndrome, signaling a long-term commitment to innovation. Ongoing Phase III trials for premenstrual syndrome treatments aimed to enroll a total of 8,500 patients as of the first quarter of 2025. This level of activity underscores a deep investment in addressing unmet medical needs.
Request Sample Pages: https://www.astuteanalytica.com/request-sample/premenstrual-syndrome-treatment-market
The research momentum is supported by strong collaborative and intellectual property efforts. In 2025, 9 new academic-industry partnerships were formed to advance premenstrual syndrome research. Meanwhile, 2024 saw the filing of 45 patents for new premenstrual syndrome treatment formulations, protecting novel delivery systems and compounds. The scientific community is also contributing heavily, with 18 investigator-initiated research grants awarded for studying premenstrual syndrome etiology in 2024. Additionally, 30 research papers were published on the crucial gut-brain axis in relation to premenstrual syndrome symptoms, broadening the scientific understanding of the condition.
Key Findings in Premenstrual Syndrome Treatment Market
| Market Forecast (2033) | US$ 2,155 million |
| CAGR | 4.1% |
| Largest Region (2024) | North America (Dominant) |
| By Drug Type | Analgesics (Dominant) |
| By Type | OTC (71%) |
| By Distribution Channel | Drug Stores and Retail Pharmacies (Dominant) |
| Top Drivers |
|
| Top Trends |
|
| Top Challenges |
|
Digital Health Revolutionizes Patient Engagement and Personalized Care Within the Premenstrual Syndrome Space
FemTech is fundamentally altering how individuals manage their symptoms. The digital health sector is a major growth catalyst for the Premenstrual syndrome treatment market. The top 5 premenstrual syndrome tracking apps onboarded 2.5 million new users in the first quarter of 2025 alone. Accessibility to care has improved dramatically, evidenced by the 1.2 million telehealth consultations for premenstrual syndrome-related symptoms conducted in 2024. This digital shift reflects a broader trend toward patient empowerment and data-driven health management, creating new avenues for market players.
Innovation extends beyond apps to more integrated and immersive technological solutions in the premenstrual syndrome treatment market. By 2025, 15 wearable tech companies had integrated menstrual cycle prediction and symptom logging features into their devices. In 2024, 10 new AI-powered chatbots for menstrual health support were launched, providing instant assistance. Educational podcasts on the subject saw 500,000 downloads in the same year. Moreover, 7 pilot programs are testing virtual reality (VR) based relaxation therapies for premenstrual syndrome anxiety in 2025, and 14 FemTech startups focused on premenstrual syndrome solutions received crucial seed funding in 2024.
Surging Consumer Demand for OTC Products Reshapes Retail Market Access Strategies Across Premenstrual Syndrome Treatment Market
Consumer purchasing habits show a clear preference for accessible, non-prescription solutions. Over-the-counter (OTC) products are a dominant force, with sales of magnesium supplements for premenstrual syndrome relief reaching 15 million units in 2024. The market for natural remedies is also booming; 6 million units of chasteberry supplements were sold in 2024. This trend is further supported by 3 million consumer inquiries made to pharmacists regarding OTC premenstrual syndrome treatments during the same year, highlighting a proactive approach to self-care.
Product innovation in the OTC space is rampant and responsive to consumer needs. In 2025, 20 new herbal tea formulations for premenstrual syndrome were launched. Concurrently, sales of menstrual heating patches hit 4 million units in the fourth quarter of 2024. The market also saw the introduction of 8 new topical analgesic creams for menstrual pain in 2024. Online consumer interest is massive, with 18 million searches for “natural premenstrual syndrome remedies” recorded in 2025. These figures demonstrate a clear and growing demand for non-pharmaceutical interventions within the Premenstrual syndrome treatment market.
Prescription Drug Sector Demonstrates Strong Growth and Expanding Therapeutic Treatment Options
The prescription segment of the Premenstrual syndrome treatment market is characterized by robust activity. In 2024, healthcare providers wrote 750,000 new prescriptions for SSRIs to treat premenstrual dysphoric disorder. Patient access and support remain a priority; 15,000 new patients were enrolled in assistance programs for a leading premenstrual dysphoric disorder medication in 2025. The market is also seeing new entrants, with 5 countries approving a new gonadotropin-releasing hormone (GnRH) antagonist for premenstrual dysphoric disorder by 2024. These developments signify a healthy and evolving prescription landscape.
Physician engagement and patient consultations are key drivers of this segment’s growth in the premenstrual syndrome treatment market. In 2024, healthcare professionals completed 25,000 continuing medical education (CME) programs focused on premenstrual dysphoric disorder diagnosis and treatment. That same year, there were 4.5 million patient visits to gynecologists with a primary complaint of premenstrual syndrome. Furthermore, 2 million prescriptions for oral contraceptives were written specifically for premenstrual syndrome symptom management in 2025. Underscoring these trends, 12 health insurance providers expanded their coverage for premenstrual dysphoric disorder treatments in 2024, improving patient access to necessary medications.
Nutraceuticals and Dietary Supplements Carve a Significant Niche in Premenstrual Syndrome Treatment Market
There is a growing consumer trust in targeted nutritional support for premenstrual syndrome. The nutraceutical segment is thriving, with sales of Vitamin B6 as a premenstrual syndrome supplement reaching 50 tons in 2024. The market for omega-3 fatty acids for menstrual health saw consumer spending hit $50 million in the same year. Innovation continues with the launch of 11 new calcium and Vitamin D combination products in 2025. This focus on specific micronutrients provides a strong opportunity for growth in the overall Premenstrual syndrome treatment market.
Scientific backing and retail expansion are fueling the nutraceutical boom. In 2024, 6 new clinical studies were published on the efficacy of evening primrose oil for premenstrual syndrome. Retail outlets are responding to demand, with 10,000 stores stocking a new line of premenstrual syndrome-focused gummy supplements by 2025. The market for botanicals is also strong, with 2 million units of Ginkgo biloba supplements sold for cognitive symptoms in 2024. Reflecting a clean-label trend, the number of certified organic premenstrual syndrome supplement product lines available is set to reach 30 in 2025.
Key Players Intensify Competition in the Hormonal Contraceptives Treatment Segment Market
The hormonal contraceptives segment is a competitive battleground in the premenstrual syndrome treatment market. Bayer AG saw 300,000 new patient starts on a leading COC for premenstrual dysphoric disorder in 2024 and sold 25 million units of a specific drospirenone-containing pill. The company spent $15 million on direct-to-consumer advertising for a key treatment and distributed 1 million physician samples of a new low-dose contraceptive in Q1 2025. It is also researching 3 new indications for an existing product and conducted 500 healthcare professional outreach programs in 2025, while its brand website featured 50 patient testimonials in 2024.
Other major players are equally active in the premenstrual syndrome treatment market. Pfizer Inc. enrolled 10,000 women in post-market surveillance studies for a new contraceptive injection in 2024 and received regulatory approval for a new COC in 8 countries. The company has 150 medical liaisons in key markets in 2025, launched 12 digital marketing campaigns in 2024, held 20 webinars for providers, and formed 6 collaborations with women’s health organizations. It also sold 10 million units of a specific contraceptive patch in 2024. Meanwhile, AbbVie Inc. initiated 2 clinical trials for a new premenstrual dysphoric disorder indication in 2024 and invested $200 million in its women’s health R&D pipeline. Its sales force includes 800 representatives, it distributed 2 million patient education brochures, and published 18 related articles in peer-reviewed journals in 2024. The company also provided co-pay assistance to 20,000 patients and delivered 15 presentations at major conferences in 2025.
Evolving Regulatory Frameworks and Professional Education Bolster Market Confidence and Growth
A supportive professional and regulatory environment is crucial for market expansion. In 2024, 3 new drug applications for premenstrual syndrome treatments were submitted to the FDA. The European Medicines Agency granted 2 fast-track designations for novel premenstrual dysphoric disorder therapies in 2025. In a move to accelerate development, 5 public-private partnerships were formed in 2024. Regulators are also actively refining standards, with 4 advisory committee meetings held in 2025 to discuss new endpoints for premenstrual syndrome clinical trials, building a clear path for innovation in the Premenstrual syndrome treatment market.
Simultaneously, healthcare professional education is surging. A major international women’s health conference drew 15,000 attendees in 2024. That same year, 50,000 primary care physicians completed online modules on premenstrual syndrome, and 1,200 grand rounds on severe premenstrual syndrome were held in teaching hospitals. Medical societies issued 4 new clinical practice guidelines in 2025, and a leading journal of women’s health reached 80,000 provider subscriptions. This educational push is supported by the 3,500 newly registered nurse practitioners specializing in women’s health in 2024 and 10,000 clinician downloads of a new premenstrual dysphoric disorder diagnostic tool app in 2025. Additionally, 9 major insurers changed reimbursement policies for psychological therapies in 2025, and 7 health technology assessments of new treatments were completed in 2024. The regulatory landscape also saw 1 orphan drug designation for severe premenstrual disorders in 2024.
Expanding Global Access and Regional Demand Create New Avenues for Market Penetration Across Premenstrual Syndrome Treatment Market
Efforts to improve access are creating new opportunities in underserved regions. By 2025, 500 community health centers in low- and middle-income countries will have integrated menstrual health services. In 2024, 15 non-governmental organizations launched premenstrual syndrome awareness campaigns in Southeast Asia. Online pharmacies are also expanding their reach, with 30 of them extending their premenstrual syndrome product delivery to remote areas in 2024. These initiatives are critical for unlocking the full potential of the global Premenstrual syndrome treatment market.
Demand is also growing in developed regions, driven by progressive policies and programs. By 2025, 2,000 workplace wellness programs in Europe will include menstrual health support. Governments are taking notice, with 6 government-funded studies on the economic impact of premenstrual syndrome in the workplace initiated in 2024. The global health community is contributing through 40 medical missions providing gynecological care in 2025. To support global understanding, premenstrual syndrome educational materials were translated into 25 new languages in 2024, fostering greater awareness and demand worldwide.
Need a Detailed Walkthrough of the Report? Request a Live Session: https://www.astuteanalytica.com/expert-call/premenstrual-syndrome-treatment-market
Powerful Patient Advocacy Efforts Are Now Driving Awareness and Influencing Market Trends
The patient voice has become a formidable force in shaping the premenstrual syndrome treatment market. The leading international premenstrual dysphoric disorder patient support organization welcomed 10,000 new members in 2024. That same year, a petition for increased research funding for premenstrual dysphoric disorder garnered 100,000 signatures. Patient stories are now a powerful tool, with 1,500 of them shared on a major premenstrual dysphoric disorder awareness platform in 2024. This groundswell of advocacy is reducing stigma and creating a more supportive environment.
This advocacy translates directly into community support and political action. In 2025, 3,000 online support group meetings for premenstrual syndrome and premenstrual dysphoric disorder will be held. A peer support hotline for severe premenstrual syndrome trained 200 new volunteers in 2025. Community-led fundraising is also impactful, with 50 events held globally for premenstrual dysphoric disorder research and awareness in 2024. These efforts are having a tangible policy impact, with 3 legislative initiatives to recognize premenstrual dysphoric disorder as a serious health condition introduced in 2025, directly influencing the future of the Premenstrual syndrome treatment market.
Premenstrual Syndrome Treatment Market Major Players:
- AbbVie Inc.
- BASF SE
- Bayer AG
- Dr. Reddy’s Laboratories Ltd
- Eli Lilly and Company
- GlaxoSmithKline Plc.
- H. Lundbeck A/S
- Pfizer Inc.
- SHIONOGI & Co. Ltd.
- MetP Pharma AG
- Umecrine Mood AB
- Other Prominent Players
Key Market Segmentation:
By Type
- Prescription
- OTC
By Drug Type
- Analgesics
- Antidepressants
- Oral Contraceptives and Ovarian Suppression Agents
- Others
By Distribution Channel
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Providers
By Region
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- South America
Need a Customized Version? Request It Now: https://www.astuteanalytica.com/ask-for-customization/premenstrual-syndrome-treatment-market
About Astute Analytica
Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements.
With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace.
Contact Us:
Astute Analytica
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
For Sales Enquiries: sales@astuteanalytica.com
Website: https://www.astuteanalytica.com/
Follow us on: LinkedIn | Twitter | YouTube
CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@astuteanalytica.com Website: https://www.astuteanalytica.com/
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.